Table 2. Association between serum cytokeratin19-2G2 and clinicopathological characteristics in PBC patients.
| Characteristics | N | Serum CK19-2G2 | levels (mU/mL) | P value |
| <2 | ≥2 | |||
| Age (years) | 249 | 0.355 | ||
| ≤35 | 21 | 6 | ||
| >35 | 192 | 30 | ||
| Menopausal status | 249 | 0.542 | ||
| Premenopausal | 124 | 19 | ||
| Postmenopausal | 89 | 17 | ||
| Stage | 230 | <0.001* | ||
| I, II | 153 | 18 | ||
| III | 41 | 18 | ||
| Tumor size (cm) | 230 | 0.020* | ||
| ≤2 | 64 | 5 | ||
| >2 | 124 | 30 | ||
| Lymphonodes status | 245 | 0.019* | ||
| Negative | 108 | 11 | ||
| Positive | 101 | 25 | ||
| ER status | 245 | 0.006* | ||
| Negative | 72 | 21 | ||
| Positive | 137 | 15 | ||
| PR status | 245 | 0.118 | ||
| Negative | 87 | 24 | ||
| Positive | 122 | 12 | ||
| CerbB2 status | 234 | 0.005* | ||
| Negative | 159 | 24 | ||
| Positive | 49 | 12 |
*
P value <0.05, statistically significant.